Thomas Sara L, Walker Jemma L, Fenty Justin, Atkins Katherine E, Elliot Alex J, Hughes Helen E, Stowe Julia, Ladhani Shamez, Andrews Nick J
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK; Immunisation, Hepatitis and Blood Safety Department, Centre for Infectious Disease Surveillance and Control (CIDSC), Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK.
Vaccine. 2017 Jan 23;35(4):680-686. doi: 10.1016/j.vaccine.2016.11.057. Epub 2016 Dec 20.
Introduction of infant oral rotavirus vaccination in the UK in July 2013 has resulted in decreased hospitalisations and Emergency Department (ED) visits for acute gastroenteritis (AGE), for both adults and children. We investigated reductions in AGE incidence seen in primary care in the two years after vaccine introduction, and estimated the healthcare costs averted across healthcare settings in the first year of the vaccination programme.
We used primary care data from the Clinical Practice Research Datalink and age-stratified time-series analyses to derive adjusted incidence rate ratios (IRR) for AGE in the first two years of the post-vaccination era (July 2013-April 2015) compared to the pre-vaccination era (July 2008-June 2013). We estimated cases averted among children aged <5years in the first year of the vaccination programme by comparing observed numbers of AGE cases in 2013-2014 to numbers predicted from the time-series models. We then estimated the healthcare costs averted for general practice consultations, ED visits and hospitalisations.
In general practice, AGE rates in infants (the target group for vaccination) decreased by 15% overall after vaccine introduction (IRR=0.85; 95%CI=0.76-0.95), and by 41% in the months of historically high rotavirus circulation (IRR=0.59; 95%CI=0.53-0.66). Rates also decreased in other young children and to a lesser degree in older individuals, indicating herd immunity. Across all three settings (general practice, EDs, and hospitalisations) an estimated 87,376 (95% prediction interval: 62,588-113,561) AGE visits by children aged <5years were averted in 2013-14, associated with an estimated £12.5million (9,209-16,198) reduction in healthcare costs.
The marked decreases in the general practice AGE burden after rotavirus vaccine introduction mirror decreases seen in other UK healthcare settings. Overall, these decreases are associated with substantial averted healthcare costs.
2013年7月英国引入婴儿口服轮状病毒疫苗后,成人和儿童因急性胃肠炎(AGE)住院及前往急诊科就诊的人数均有所减少。我们调查了疫苗引入后两年内初级保健中AGE发病率的下降情况,并估算了疫苗接种计划第一年在所有医疗环境中避免的医疗费用。
我们使用临床实践研究数据链中的初级保健数据以及年龄分层的时间序列分析,得出疫苗接种后时代(2013年7月至2015年4月)前两年与疫苗接种前时代(2008年7月至2013年6月)相比AGE的调整发病率比(IRR)。通过比较2013 - 2014年观察到的AGE病例数与时间序列模型预测的病例数,我们估算了疫苗接种计划第一年5岁以下儿童中避免的病例数。然后我们估算了在全科诊疗、急诊科就诊和住院方面避免的医疗费用。
在初级保健中,疫苗引入后婴儿(疫苗接种目标群体)的AGE发病率总体下降了15%(IRR = 0.85;95%CI = 0.76 - 0.95),在轮状病毒历史高发传播月份下降了41%(IRR = 0.59;95%CI = 0.53 - 0.66)。其他幼儿的发病率也有所下降,年长者下降程度较小,表明存在群体免疫。在所有三种环境(全科诊疗、急诊科和住院)中,2013 - 14年估计避免了5岁以下儿童87376次(95%预测区间:62588 - 113561)AGE就诊,估计医疗费用减少了1250万英镑(9209 - 16198)。
引入轮状病毒疫苗后初级保健中AGE负担的显著下降与英国其他医疗环境中的下降情况一致。总体而言,这些下降与大量避免的医疗费用相关。